273 related articles for article (PubMed ID: 35087759)
21. New developments in the management of Waldenström macroglobulinemia.
Abeykoon JP; Yanamandra U; Kapoor P
Cancer Manag Res; 2017; 9():73-83. PubMed ID: 28331368
[TBL] [Abstract][Full Text] [Related]
22. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
23. Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.
Berendsen MR; van Bladel DAG; Hesius E; Berganza Irusquieta C; Rijntjes J; van Spriel AB; van der Spek E; Pruijt JFM; Kroeze LI; Hebeda KM; Croockewit S; Stevens WBC; van Krieken JHJM; Groenen PJTA; van den Brand M; Scheijen B
Hemasphere; 2023 Nov; 7(11):e976. PubMed ID: 37928625
[TBL] [Abstract][Full Text] [Related]
24. [Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
Zhang DD; Hu PZ; Li P; Jiang GZ; Yin YH; Wang GN; Zhao WG; Zhang YP; Li WC
Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):592-597. PubMed ID: 34078045
[No Abstract] [Full Text] [Related]
25. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with Hodgkin disease. A report of two cases.
Rosales CM; Lin P; Mansoor A; Bueso-Ramos C; Medeiros LJ
Am J Clin Pathol; 2001 Jul; 116(1):34-40. PubMed ID: 11447749
[TBL] [Abstract][Full Text] [Related]
26. Reducing treatment toxicity in Waldenström macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Expert Opin Drug Saf; 2021 Jun; 20(6):669-676. PubMed ID: 33645373
[No Abstract] [Full Text] [Related]
27. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
Castillo JJ; Palomba ML; Advani R; Treon SP
Ther Adv Hematol; 2016 Aug; 7(4):179-86. PubMed ID: 27493708
[TBL] [Abstract][Full Text] [Related]
28. Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.
Ashruf OS; Mirzai S; George LL; Anwer F
Int J Hematol Oncol; 2023 Jun; 12(2):IJH44. PubMed ID: 37304326
[TBL] [Abstract][Full Text] [Related]
29. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
30. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
31. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.
Maqbool MG; Tam CS; Morison IM; Simpson D; Mollee P; Schneider H; Chan H; Juneja S; Harvey Y; Nath L; Hissaria P; Prince HM; Wordsworth H; Opat S; Talaulikar D
Pathology; 2020 Feb; 52(2):167-178. PubMed ID: 31902622
[TBL] [Abstract][Full Text] [Related]
32. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
Zanwar S; Abeykoon JP
Ther Adv Hematol; 2022; 13():20406207221093962. PubMed ID: 35510210
[TBL] [Abstract][Full Text] [Related]
33. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
36. Waldenström macroglobulinemia: What a hematologist needs to know.
Kapoor P; Paludo J; Vallumsetla N; Greipp PR
Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617
[TBL] [Abstract][Full Text] [Related]
37. Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
Shin SY; Lee ST; Kim HY; Park CH; Kim HJ; Kim JW; Kim SJ; Kim WS; Kim SH
Blood Res; 2016 Sep; 51(3):181-186. PubMed ID: 27722129
[TBL] [Abstract][Full Text] [Related]
38. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
[TBL] [Abstract][Full Text] [Related]
39. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]